| Name | Title | Contact Details |
|---|---|---|
Hannah Willson |
Chief Revenue Officer | Profile |
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Sano Informed Prescribing, Inc. is creating game-changing personal and population health management capabilities, previously unattainable in the healthcare market, by revolutionizing medication therapy through the fast, clinically precise detection of medications in patients. The vision of Sano Informed Prescribing is to improve individual and population health; enable healthcare professionals to evaluate, adjust and implement best possible medication therapy programs; and reduce the costs associated with quality healthcare. Sano Informed Prescribing’s mission is to ensure that every patient receives the most effective drug therapy possible. We will do this by providing precise, patient-specific medication analyses that empower healthcare professionals to tailor care; achieve optimal patient health outcomes and satisfaction; and impact overall healthcare costs.
Paramount Pharmacies Limited is a New Waterford, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.